Business
Director/PDMR Shareholding
David Hallas, Chief Executive Officer of Eco Animal Health Group plc, purchased 18,348 ordinary shares at 109 pence per share on December 4, 2025. Following this transaction, Mr. Hallas now holds 203,041 ordinary shares, representing approximately 0.29% of the company's issued share capital. This purchase by a key executive may be viewed positively by investors as a sign of confidence in the company's future prospects. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n04 December 2025\n\n\nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nShare Purchase by Executive Director\n ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that on 04 December 2025 David Hallas, Chief Executive Officer, purchased 18,348 ordinary shares in the Company (\"Ordinary Shares\") at 109 pence per Ordinary Share. Following this, Mr Hallas holds 203,041 Ordinary Shares, representing approximately 0.29 per cent. of the Company's issued share capital.\n-Ends-\nFor further information please contact:\n\n\n\n\n\n\n\n\n \nECO Animal Health Group plc\nDavid Hallas (Chief Executive Officer)\nChristopher Wilks (Chief Financial Officer)\n \n\n\n 020 8447 8899\n\n\n\n\nICR Healthcare (Financial PR)\nMary-Jane Elliott\nJessica Hodgson\n \n\n\n020 3709 5700\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Joint Broker)\nPhilip Davies\nSam Butcher\nSamed Ethemi\n \n \n\n\n020 7496 3000\n\n\n\n\nPanmure Liberum (Joint Broker)\nEmma Earl\nWill Goode\nMark Rogers\nRupert Dearden\n \n \n\n\n020 3100 2000 \n \n \n\n\n\n\nEquity Development\nHannah Crowe\nMatt Evans\n\n\n020 7065 2692\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \nAbout ECO Animal Health\nECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.\nHeadquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.\nOur lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. \nClick here for more information: https://ecoanimalhealth.com\n \n \nPDMR Notification\n\n\n\n\n1. \n\n\nDetails of the person discharging managerial responsibilities / person closely associated\n\n\n\n\na. \n\n\nName\n\n\nDavid...